10. REFERENCES

1.	World Health Organization. WHO COVID-19 Dashboard. Geneva [Internet]. 2020. Available from: https://covid19.who.int
2.	Cao W, Li T. COVID-19: towards understanding of pathogenesis. Cell Res [Internet]. 2020 May 1;30(5):367Ð9. Available from: https://www.nature.com/articles/s41422-020-0327-4
3.	Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. New England Journal of Medicine [Internet]. 2020 Dec 17;383(25):2451Ð60. Available from: https://www.nejm.org/doi/10.1056/NEJMcp2009575
4.	Chams N, Chams S, Badran R, Shams A, Araji A, Raad M, et al. COVID-19: A Multidisciplinary Review [Internet]. Vol. 8, Frontiers in Public Health. Frontiers Media S.A.; 2020. Available from: https://www.frontiersin.org/articles/10.3389/fpubh.2020.00383/full
5.	Fajgenbaum DC, June CH. Cytokine Storm. New England Journal of Medicine [Internet]. 2020 Dec 3;383(23):2255Ð73. Available from: https://www.nejm.org/doi/full/10.1056/NEJMra2026131
6.	Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment [Internet]. Vol. 97, Postgraduate Medical Journal. BMJ Publishing Group; 2021. p. 312Ð20. Available from: https://academic.oup.com/pmj/article/97/1147/312/6969661
7.	Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention [Internet]. Vol. 323, JAMA - Journal of the American Medical Association. American Medical Association; 2020. p. 1239Ð42. Available from: https://jamanetwork.com/journals/jama/fullarticle/2762130
8.	Gandhi RT, Lynch JB, del Rio C. Mild or Moderate Covid-19. New England Journal of Medicine [Internet]. 2020 Oct 29;383(18):1757Ð66. Available from: https://www.nejm.org/doi/full/10.1056/nejmcp2009249
9.	Gattinoni L, Chiumello D, Caironi P, Busana M. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med [Internet]. 2020;46:1099Ð102. Available from: https://link.springer.com/article/10.1007/s00134-020-06033-2
10.	Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. New England Journal of Medicine [Internet]. 2020 Apr 23;382(17):e38. Available from: https://www.nejm.org/doi/full/10.1056/nejmc2007575
11.	Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet [Internet]. 2020 Mar 28;395(10229):1054Ð62. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30566-3/fulltext
12.	Alharthy A, Aletreby W, Faqihi F, Balhamar A, Alaklobi F, Alanezi K, et al. Clinical characteristics and predictors of 28-day mortality in 352 critically ill patients with COVID-19: A retrospective study. J Epidemiol Glob Health [Internet]. 2021 Mar 1;11(1):98Ð108. Available from: https://www.atlantis-press.com/journals/jegh/125944793
13.	Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature [Internet]. 2020 Aug 20;584(7821):430Ð6. Available from: https://www.nature.com/articles/s41586-020-2521-4
14.	Albitar O, Ballouze R, Ooi JP, Sheikh Ghadzi SM. Risk factors for mortality among COVID-19 patients. Diabetes Res Clin Pract [Internet]. 2020 Aug 1;166. Available from: https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(20)30545-3/fulltext
15.	Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis [Internet]. 2021 Dec 1;21(1). Available from: https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06536-3
16.	Izcovich A, Ragusa MA, Tortosa F, Marzio MAL, Agnoletti C, Bengolea A, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review. PLoS One [Internet]. 2020 Nov 1;15(11 November). Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0241955
17.	Parohan M, Yaghoubi S, Seraji A, Javanbakht MH, Sarraf P, Djalali M. Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies [Internet]. Vol. 23, Aging Male. Taylor and Francis Ltd.; 2021. p. 1416Ð24. Available from: https://www.tandfonline.com/doi/full/10.1080/13685538.2020.1774748
18.	Gao Y dong, Ding M, Dong X, Zhang J jin, Kursat Azkur A, Azkur D, et al. Risk factors for severe and critically ill COVID-19 patients: A review [Internet]. Vol. 76, Allergy: European Journal of Allergy and Clinical Immunology. Blackwell Publishing Ltd; 2021. p. 428Ð55. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/all.14657
19.	Instituto nacional de salud. COVID 19 en Colombia [Internet]. 2020. Available from: https://www.ins.gov.co/Noticias/Paginas/Coronavirus.aspx
20.	Senser DJ. CDC Museum COVID-19 Timeline [Internet]. 2022. Available from: https://www.cdc.gov/museum/timeline/covid19.html
21.	Carvalho T, Krammer F, Iwasaki A. The first 12 months of COVID-19: a timeline of immunological insights [Internet]. Vol. 21, Nature Reviews Immunology. Nature Research; 2021. p. 245Ð56. Available from: https://www.nature.com/articles/s41577-021-00522-1
22.	Ritchie H, Mathieu E. Coronavirus Pandemic (COVID-19) [Internet]. 2020. Available from: https://ourworldindata.org/coronavirus
23.	PAHO. Geo-Hub COVID-19 - Information System for the Region of the Americas [Internet]. 2022. Available from: https://paho-covid19-response-who.hub.arcgis.com
24.	SALUDATA. Casos confirmados de COVID-19 en Bogota, D.C [Internet]. 2022. Available from: https://saludata.saludcapital.gov.co/osb/index.php/datos-de-salud/enfermedades-trasmisibles/covid19/
25.	Mallick R, Duttaroy A. Origin and Structural Biology of Novel Coronavirus (SARS-CoV-2). In: Coronavirus Therapeutics [Internet]. 2020. p. 1Ð30. Available from: https://link.springer.com/chapter/10.1007/978-3-030-85109-5_1
26.	Lam TTY, Jia N, Zhang YW, Shum MHH, Jiang JF, Zhu HC, et al. Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins. Nature [Internet]. 2020 Jul 9;583(7815):282Ð5. Available from: https://www.nature.com/articles/s41586-020-2169-0
27.	Cascella M, Rajnik M, Aleem A. Features, Evaluation, and Treatment of Coronavirus (COVID-19) [Internet]. NCBI Bookshelf; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554776/
28.	Rolim Neto ML, Lima da Silva CG. Epidemiology and Etiopathogeny of COVID-19. In: Coronavirus Therapeutics [Internet]. 2020. p. 45Ð92. Available from: https://link.springer.com/chapter/10.1007/978-3-030-85109-5_4
29.	Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. Journal of Pathology [Internet]. 2004 Jun;203(2):631Ð7. Available from: https://pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/path.1570
30.	Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The incubation period of coronavirus disease 2019 (CoVID-19) from publicly reported confirmed cases: Estimation and application. Ann Intern Med [Internet]. 2020 May 5;172(9):577Ð82. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081172/
31.	National Institutes of Health. Clinical Spectrum of SARS-CoV-2 Infection. COVID-19 Treatment Guidelines panel [Internet]. 2022; Available from: https://www.covid19treatmentguidelines.nih.gov/
32.	Bartoli A, Gabrielli F, Alicandro T, Nascimbeni F, Andreone P. COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs [Internet]. Vol. 16, Internal and Emergency Medicine. Springer Science and Business Media Deutschland GmbH; 2021. p. 281Ð308. Available from: https://link.springer.com/article/10.1007/s11739-020-02569-9
33.	Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al. Acute respiratory distress syndrome: The Berlin definition. JAMA [Internet]. 2012 Jun 13;307(23):2526Ð33. Available from: https://jamanetwork.com/journals/jama/article-abstract/1160659
34.	Malik P, Patel U, Mehta D, Patel N, Kelkar R, Akrmah M, et al. Biomarkers and outcomes of COVID-19 hospitalisations: Systematic review and meta-analysis [Internet]. Vol. 26, BMJ Evidence-Based Medicine. BMJ Publishing Group; 2021. p. 107Ð8. Available from: https://ebm.bmj.com/content/26/3/107.long
35.	Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro [Internet]. Vol. 30, Cell Research. Springer Nature; 2020. p. 269Ð71. Available from: https://www.nature.com/articles/s41422-020-0282-0
36.	National Institutes of Health. Coronavirus Disease 2019 (COVID-19) treatment guidelines. COVID-19 Treatment Guidelines Panel [Internet]. 2022; Available from: https://www.covid19treatmentguidelines.nih.gov/
37.	Gold MS, Sehayek D, Gabrielli S, Zhang X, McCusker C, Ben-Shoshan M. COVID-19 and comorbidities: a systematic review and meta-analysis. Postgrad Med [Internet]. 2020;749Ð55. Available from: https://www.tandfonline.com/doi/abs/10.1080/00325481.2020.1786964?journalCode=ipgm20
38.	Zhao Z, Chen A, Hou W, Graham JM, Li H, Richman PS, et al. Prediction model and risk scores of ICU admission and mortality in COVID-19. PLoS One [Internet]. 2020 Jul 1;15(7 July). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392248/
39.	Liu W, Yang C, Liao Y gao, Wan F, Lin L, Huang X, et al. Risk factors for COVID-19 progression and mortality in hospitalized patients without pre-existing comorbidities. J Infect Public Health [Internet]. 2022 Jan 1;15(1):13Ð20. Available from: https://www.sciencedirect.com/science/article/pii/S1876034121003762?via%3Dihub
40.	FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. 2016. Available from: https://www.ncbi.nlm.nih.gov/books/NBK326791/
41.	Pepys MB, Hirschfield GM. C-reactive protein: A critical update [Internet]. Vol. 111, Journal of Clinical Investigation. 2003. p. 1805Ð12. Available from: https://www.jci.org/articles/view/18921
42.	Gallo Marin B, Aghagoli G, Lavine K, Yang L, Siff EJ, Chiang SS, et al. Predictors of COVID-19 severity: A literature review [Internet]. Vol. 31, Reviews in Medical Virology. John Wiley and Sons Ltd; 2021. p. 1Ð10. Available from: https://onlinelibrary.wiley.com/doi/10.1002/rmv.2146
43.	Manry Jeremy. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. PNAS [Internet]. 2022;119(21). Available from: https://doi.org/10.1073/pnas.2200413119
44.	Adam SS, Key NS, Greenberg CS. D-dimer antigen: Current concepts and future prospects [Internet]. Vol. 113, Blood. American Society of Hematology; 2009. p. 2878Ð87. Available from: https://ashpublications.org/blood/article/113/13/2878/24753/D-dimer-antigen-current-concepts-and-future
45.	Horsti J, Uppa H, Vilpo JA. Poor agreement among prothrombin time international normalized ratio methods: Comparison of seven commercial reagents. Clin Chem [Internet]. 2005 Mar;51(3):553Ð60. Available from: https://academic.oup.com/clinchem/article/51/3/553/5629768?login=false
46.	Piera Carbonell A, Fr’as Vargas M, Garc’a Vallejo O, Garc’a Ler’n A, Cabrera Ferriols MA, Peir— Morant J, et al. COVID-19 and thromboprophylaxis: Recommendations for our clinical practice in Primary Care. Semergen [Internet]. 2020 Oct 1;46(7):479Ð86. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500906/
47.	Toraih EA, Elshazli RM, Hussein MH, Elgaml A, Amin M, El-Mowafy M, et al. Association of cardiac biomarkers and comorbidities with increased mortality, severity, and cardiac injury in COVID-19 patients: A meta-regression and decision tree analysis [Internet]. Vol. 92, Journal of Medical Virology. John Wiley and Sons Inc; 2020. p. 2473Ð88. Available from: https://onlinelibrary.wiley.com/doi/10.1002/jmv.26166
48.	Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19 [Internet]. Vol. 97, Kidney International. Elsevier B.V.; 2020. p. 829Ð38. Available from: https://www.kidney-international.org/article/S0085-2538(20)30255-6/fulltext
49.	Piano S, Dalbeni A, Vettore E, Benfaremo D, Mattioli M, Gambino CG, et al. Abnormal liver function tests predict transfer to intensive care unit and death in COVID-19. Liver International [Internet]. 2020 Oct 1;40(10):2394Ð406. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307119/
50.	van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. J Stat Softw [Internet]. 2011;45(3):1Ð67. Available from: https://www.jstatsoft.org/index.php/jss/article/view/v045i03
51.	MINISTERIO DE SALUD. RESOLUCION NUMERO 8430 DE 1993 [Internet]. 1993. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/RESOLUCION-8430-DE-1993.PDF
52.	Araujo M, Ossand—n P, Abarca AM, Menjiba AM, Mu–oz AM. Pron—stico de pacientes hospitalizados por COVID-19 en un centro terciario en Chile: estudio de cohorte. Medwave. 2020 Nov 17;20(10):e8066. Available from: https://www.medwave.cl/investigacion/estudios/8066.html
53.	Alonso R, Camon AM, Cardozo C, Albiach L, AgŸero D, Marcos MA, et al. Clinical Presentation and Outcome of COVID-19 in a Latin American Versus Spanish Population: Matched Case-Control Study. Infect Dis Ther [Internet]. 2022 Jun 1 [cited 2022 Sep 23];11(3):1243Ð51. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043505/
54.	Lei F, Liu YM, Zhou F, Qin JJ, Zhang P, Zhu L, et al. Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China. Hepatology [Internet]. 2020 Aug 1 [cited 2022 Sep 23];72(2):389Ð98. Available from: https://journals.lww.com/hep/Abstract/2020/08000/Longitudinal_Association_Between_Markers_of_Liver.5.aspx
55.	Russo A, Pisaturo M, Palladino R, Maggi P, Numis FG, Gentile I, et al. Prognostic Value of Transaminases and Bilirubin Levels at Admission to Hospital on Disease Progression and Mortality in Patients with COVID-19-An Observational Retrospective Study. Pathogens [Internet]. 2022 Jun 1 [cited 2022 Sep 23];11(6). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227474/
56.	Dawood DRM, Salum GM, El-Meguid MA. The Impact of COVID-19 on Liver Injury. Am J Med Sci [Internet]. 2022 Feb 1 [cited 2022 Sep 23];363(2):94Ð103. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571104/
57.	Zhou S, Li H, Li S. The Associations of Iron Related Biomarkers with Risk, Clinical Severity and Mortality in SARS-CoV-2 Patients: A Meta-Analysis. Nutrients [Internet]. 2022 Aug 1 [cited 2022 Sep 23];14(16). Available from: https://www.mdpi.com/2072-6643/14/16/3406
58.	Dahan S, Segal G, Katz I, Hellou T, Tietel M, Bryk G, et al. Ferritin as a Marker of Severity in COVID-19 Patients: A Fatal Correlation. Isr Med Assoc J [Internet]. 2020 Aug 1 [cited 2022 Sep 23];22(8):494Ð500. Available from: https://www.ima.org.il/MedicineIMAJ/viewarticle.aspx?year=2020&month=08&page=494
59.	Litton E, Lim J. Iron Metabolism: An Emerging Therapeutic Target in Critical Illness. Crit Care [Internet]. 2019 Mar 9 [cited 2022 Sep 23];23(1). Available from: https://ccforum.biomedcentral.com/articles/10.1186/s13054-019-2373-1
60.	Torti FM, Torti S v. Regulation of ferritin genes and protein. Blood [Internet]. 2002 May 15 [cited 2022 Sep 23];99(10):3505Ð16. Available from: https://ashpublications.org/blood/article/99/10/3505/106937/Regulation-of-ferritin-genes-and-protein
61.	Smirnov IM, Bailey K, Flowers CH, Garrigues NW, Wesselius LJ. Effects of TNF-alpha and IL-1beta on iron metabolism by A549 cells and influence on cytotoxicity. Am J Physiol [Internet]. 1999 [cited 2022 Sep 23];277(2). Available from: https://journals.physiology.org/doi/full/10.1152/ajplung.1999.277.2.L257?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org
62.	Wei Y, Miller SC, Tsuji Y, Torti S v., Torti FM. Interleukin 1 induces ferritin heavy chain in human muscle cells. Biochem Biophys Res Commun [Internet]. 1990 May 31 [cited 2022 Sep 23];169(1):289Ð96. Available from: https://www.sciencedirect.com/science/article/abs/pii/0006291X90914666
63.	Fahmy M, Young SP. Modulation of iron metabolism in monocyte cell line U937 by inflammatory cytokines: changes in transferrin uptake, iron handling and ferritin mRNA. Biochem J [Internet]. 1993 [cited 2022 Sep 23];296 ( Pt 1)(Pt 1):175Ð81. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1137671/
64.	Hirayama M, Kohgo Y, Kondo H, Shintani N, Fujikawa K, Sasaki K, et al. Regulation of iron metabolism in HepG2 cells: a possible role for cytokines in the hepatic deposition of iron. Hepatology [Internet]. 1993 [cited 2022 Sep 23];18(4):874Ð80. DOI: 10.1002/hep.1840180420
65.	Konijn AM, Carmel N, Levy R, Hershko C. Ferritin synthesis in inflammation. II. Mechanism of increased ferritin synthesis. Br J Haematol [Internet]. 1981 [cited 2022 Sep 23];49(3):361Ð70. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2141.1981.tb07238.x?sid=nlm%3Apubmed
66.	Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood [Internet]. 2009 Mar 26 [cited 2022 Sep 24];113(13):2878Ð87. Available from: https://ashpublications.org/blood/article/113/13/2878/24753/D-dimer-antigen-current-concepts-and-future
67.	Ye W, Chen G, Li X, Lan X, Ji C, Hou M, et al. Dynamic changes of D-dimer and neutrophil-lymphocyte count ratio as prognostic biomarkers in COVID-19. Respir Res [Internet]. 2020 Jul 3 [cited 2022 Sep 24];21(1). Available from: https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-020-01428-7
68.	Hilda F, Liana P, Nurtjahyo A, Hudari H, Sari NP, Umar TP, et al. D-Dimer as a Sensitive Biomarker of Survival Rate in Patients with COVID-19. Eurasian J Med [Internet]. 2022 Aug 11 [cited 2022 Sep 24]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/35950823
69.	Wong JP, Viswanathan S, Wang M, Sun LQ, Clark GC, DÕelia R v. Current and future developments in the treatment of virus-induced hypercytokinemia. Future Med Chem [Internet]. 2017 Feb 1 [cited 2022 Sep 24];9(2):169Ð78. Available from: https://www.future-science.com/doi/full/10.4155/fmc-2016-0181?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org
70.	Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost [Internet]. 2020 May 1 [cited 2022 Sep 24];18(5):1094Ð9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906401/
71.	Lee JH, Ahn JS, Chung MJ, Jeong YJ, Kim JH, Lim JK, et al. Development and Validation of a Multimodal-Based Prognosis and Intervention Prediction Model for COVID-19 Patients in a Multicenter Cohort. Sensors (Basel) [Internet]. 2022 Jul 1 [cited 2022 Sep 24];22(13). Available from: https://www.mdpi.com/1424-8220/22/13/5007
72.	Yang L, Jin J, Luo W, Gan Y, Chen B, Li W. Risk factors for predicting mortality of COVID-19 patients: A systematic review and meta-analysis. PLoS One [Internet]. 2020 Nov 1 [cited 2022 Sep 24];15(11). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7703957/
73.	Nouri-Vaskeh M, Sharifi A, Khalili N, Zand R, Sharifi A. Dyspneic and non-dyspneic (silent) hypoxemia in COVID-19: Possible neurological mechanism. Clin Neurol Neurosurg [Internet]. 2020 Nov 1 [cited 2022 Sep 24];198. Available from: https://www.sciencedirect.com/science/article/pii/S0303846720305606?via%3Dihub
74.	Villar J, Blanco J, del Campo R, Andaluz-Ojeda D, D’az-Dom’nguez FJ, Muriel A, et al. Assessment of PaO?/FiO? for stratification of patients with moderate and severe acute respiratory distress syndrome. BMJ Open [Internet]. 2015 Mar 27 [cited 2022 Sep 24];5(3). Available from: https://bmjopen.bmj.com/content/5/3/e006812.long
75.	Maraziti G, Becattini C. Early Variation of Respiratory Indexes to Predict Death or ICU Admission in Severe Acute Respiratory Syndrome Coronavirus-2-Related Respiratory Failure. Respiration [Internet]. 2022 Jul 1 [cited 2022 Sep 24];101(7):632Ð7. Available from: https://karger.com/res/article/101/7/632/826682/Early-Variation-of-Respiratory-Indexes-to-Predict
76.	Gupta GS. The Lactate and the Lactate Dehydrogenase in Inflammatory Diseases and Major Risk Factors in COVID-19 Patients. Inflammation [Internet]. 2022 [cited 2022 Sep 24];1. Available from: https://link.springer.com/article/10.1007/s10753-022-01680-7
77.	Dong X, Sun L, Li Y. Prognostic value of lactate dehydrogenase for in-hospital mortality in severe and critically ill patients with COVID-19. Int J Med Sci [Internet]. 2020 [cited 2022 Sep 24];17(14):2225Ð31. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484664/#:~:text=A%20cutoff%20value%20of%20353.5,ill%20patients%20with%20COVID%2D19.
78.	Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med [Internet]. 2020 Jul 1 [cited 2022 Sep 24];180(7):934Ð43. Available fromhttps://jamanetwork.com/journals/jamainternalmedicine/fullarticle/-2763184
79.	Henry BM, Aggarwal G, Wong J, Benoit S, Vikse J, Plebani M, et al. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. Am J Emerg Med [Internet]. 2020 Sep 1 [cited 2022 Sep 24];38(9):1722Ð6. Available from: https://www.sciencedirect.com/science/article/pii/S0735675720304368?via%3Dihub
80.	Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao Z. Plasma CRP level is positively associated with the severity of COVID-19. Ann Clin Microbiol Antimicrob [Internet]. 2020 [cited 2022 Sep 24];19(1). Available from: https://ann-clinmicrob.biomedcentral.com/articles/10.1186/s12941-020-00362-2
81.	Lavillegrand JR, Garnier M, Spaeth A, Mario N, Hariri G, Pilon A, et al. Elevated plasma IL-6 and CRP levels are associated with adverse clinical outcomes and death in critically ill SARS-CoV-2 patients: inflammatory response of SARS-CoV-2 patients. Ann Intensive Care [Internet]. 2021 Dec 1 [cited 2022 Sep 24];11(1). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7804215/
82.	P‡l K, Molnar AA, Hu?anu A, Szederjesi J, Branea I, Tim‡r ç, et al. Inflammatory Biomarkers Associated with In-Hospital Mortality in Critical COVID-19 Patients. Int J Mol Sci [Internet]. 2022 Sep 9 [cited 2022 Sep 24];23(18):10423. Available from: https://www.mdpi.com/1422-0067/23/18/10423
83.	Zadeh Hosseingholi E, Maddahi S, Jabbari S, Molavi G. Identification of High Death Risk Coronavirus Disease-19 Patients using Blood Tests. Adv Biomed Res [Internet]. 2022 [cited 2022 Sep 24];11(1):58. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482375/
84.	Amgalan A, Othman M. Hemostatic laboratory derangements in COVID-19 with a focus on platelet count. Platelets [Internet]. 2020 Aug 17 [cited 2022 Sep 24];31(6):740Ð5. Available from: https://www.tandfonline.com/doi/abs/10.1080/09537104.2020.1768523?journalCode=iplt20
85.	Yuan Y, Wang G, Chen X, Ye XL, Li XK, Li R, et al. Thrombocytopenia and increased risk of adverse outcome in COVID-19 patients. PeerJ [Internet]. 2022 Jun 30 [cited 2022 Sep 24];10. Available from: https://peerj.com/articles/13608/
86.	Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. Ann Hematol [Internet]. 2020 Jun 1 [cited 2022 Sep 24];99(6):1205Ð8. Available from: https://link.springer.com/article/10.1007/s00277-020-04019-0
87.	Carrillo-Larco RM, Altez-Fernandez C. Anosmia and dysgeusia in COVID-19: A systematic review. Wellcome Open Res [Internet]. 2020 [cited 2022 Sep 24];5. Available from: https://wellcomeopenresearch.org/articles/5-94/v1
88.	Patil N, Kalgotra P, Sundaram S, Melquist S, Parasa S, Desai M, et al. Factors associated with poor outcomes among COVID-19 patients with gastrointestinal symptoms. Gastro hep advances [Internet]. 2022 Aug [cited 2022 Sep 24]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411817/
Ê